Peregrine Pharmaceuticals to Report Fiscal Year 2008 Financial Results
Peregrine's senior management will discuss financial results for thefiscal year ended April 30, 2008 and will review recent operating highlights.A question-and-answer session will follow management's discussion. Allinterested parties are encouraged to listen to the live conference call or thearchived webcast.
The conference call and webcast will begin at 11:30 a.m. EDT/ 8:30 a.m.PDT. To listen to a live broadcast of the call over the Internet or to reviewthe archived webcast, please visit: http://www.peregrineinc.com. The webcastwill be archived on Peregrine's website for 30 days.
To listen to the conference call via telephone, please call the followingnumber approximately 10 minutes prior to the scheduled start time and requestto join the Peregrine Pharmaceuticals call: (800) 860-2442. A telephonicreplay of the conference call will be available starting approximately onehour after the conclusion of the call through July 21, 2008 by calling(877) 344-7529, passcode 382933#.
About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with aportfolio of innovative product candidates in clinical trials for thetreatment of cancer and hepatitis C virus (HCV) infection. The company ispursuing three separate clinical programs in cancer and HCV infection with itslead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary AvidBioservices, Inc. (http://www.avidbio.com), which provides development andbio-manufacturing services for both Peregrine and outside customers.Additional information about Peregrine can be found athttp://www.peregrineinc.com.Contacts: GendeLLindheim BioCom Partners Investors Media email@example.com Barbara Lindheim (800) 987-8256 (212) 918-4650
SOURCE Peregrine Pharmaceuticals, Inc.
You May Also Like